TeleECHO educational programs for healthcare providers have successfully trained physicians and other healthcare providers to fulfill the unmet needs of patients without access to specialty care, particularly osteoporosis care. In this interview with Dr. Michael Lewiecki, he introduces us to Bone Health TeleECHO. He tells us how the program works, why it’s needed and how you can launch one in your state.
Raloxifene is as effective as alendronate at preventing osteoporotic hip fractures in women, shows a new study.
An analysis of 25 trials indicates SGLT2s and metformin did not increase fracture risk and did not negatively impact bone mineral density among type 2 diabetics.
In this week's news roundup from Rheumatology Network, we feature a one-on-one interview with Dr. Michael Lewiecki of the New Mexico Clinical Research and Osteoporosis Center. He heads a virtual learning program called Bone Health TeleECHO and in this interview, he tells us how the program works, why it’s needed and how you, as a physician, can launch one in your state.
It is important for clinicians considering prescribing denosumab treatment to counsel patients before its initiation on the importance of not delaying or discontinuing injections.
New data suggests bone density measurement follow-ups within 3 years of baseline assessment are unnecessary and a potential misuse of resources.
Children with COVID-19 can develop pediatric, inflammatory multisystemic syndrome, or PIMS, which can lead to symptoms similar to that of a painful vasculitis condition called Kawasaki disease. Today we talk with Jagadeesh Bayry, Ph.D., and Caroline Galeotti, M.D., of the University of Paris who recently described in Nature Reviews Rheumatology related pediatric cases they saw in their clinic.
Osteoporosis isn't unique to older women, according to a review published in JAMA. At-risk younger women should be screened as well. In this Q&A, Dr. Carolyn J. Crandall of UCLA discusses osteoporosis screening in younger postmenopausal women.
Managing vitamin D levels may not be as straightforward as it would seem. There are factors that should be considered that are not often communicated to patients. In today's edition of Overdrive, the Rheumatology Network podcast, we talk with Dr. Suzanne Jan de Beur of Johns Hopkins University School of Medicine. She serves as director of endocrinology at Johns Hopkins Bayview Medical Center and president-elect of the American Society for Bone and Mineral Research.
A novel polygenic risk score could help identify patients at a low-risk of fracture from osteoporosis or fragility without need for additional screenings.
This article originally appeared on DiagnosticImaging.com
A new analysis is strengthening the safety profile of abaloparatide (Tymlos) in postmenopausal women to prevent risk of fracture.
In this week’s news roundup from Rheumatology Network, we highlight our most popular stories of the week including a one-on-one discussion with Dr. Vibeke Strand, a rheumatologist, immunologist and biopharmaceutical consultant who has conducted clinical trials on JAK inhibitors for rheumatoid arthritis. In this interview, Dr. Strand discusses this and other treatments in development for rheumatoid arthritis.
A new analysis suggests DOAC use was associated with a lower risk of osteoporotic fracture than warfarin.
Patients with suspected osteoporotic fractures and normal DXA rarely have normal bone, shows a new study.
Inhaled corticosteroids for asthma or COPD do not increase the risk of major osteoporotic fractures in older women, new study shows.
A steering committee of the American Society for Bone Mineral Research recently issued COVID-19 treatment guidelines for patients receiving osteoporosis treatments. In this interview, E. Michael Lewiecki, M.D., director of the New Mexico Clinical Research and Osteoporosis Center and a University of New Mexico program called Bone Health TeleECHO, shares his best practices for treating osteoporosis patients during the pandemic.
A wide range of techniques are used in research to assess bone density and quality, but dual-energy X-ray absorptiometry (DXA) is likely to remain the standard procedure used in clinical practice for the foreseeable future for most patients, predicts the co-author of a recent review of imaging-based techniques for assessing bone in rheumatology.
COVID-19 is delaying and disrupting the treatment of many patients with osteoporosis, so the American Society for Bone and Mineral Research (ASBMR) set up a steering committee of bone specialists to consider how best to manage these patients.
According to a global study carried out at the Medical Research Council Lifecourse Epidemiology Unit (MRC LEU, University of Southampton.) in collaboration with the International Osteoporosis Foundation (IOF) and the International Society for Clinical Densitometry (ISCD), the quality of bone density scanning centers is highly inconsistent and needs to be improved.
In this interview with Dr. Kamalan Jeevaratnam, a cardiac electrophysiologist with the Faculty of Health and Medical Sciences at the University of Surrey, we explore whether bisphosphonates are associated with atrial fibrillation. “There are a group of studies that show bisphosphonates are proarrhythmic and a group that show they do not cause any problem,” he said in this interview with Rheumatology Network from his home in London.
High platelet levels within the normal range might be an early indicator for increased risk of osteoporosis, study suggests.
Organic nitrates do not have clinically relevant effects on bone mineral density or bone turnover in postmenopausal women, according to a study published in the Journal of Bone and Mineral Research.
The jury is still out on whether there is a link between the use of bisphosphonates and an increased risk of atrial fibrillation, but doctors prescribing the drugs should bear in mind there may be a link, says the authors of a recent review published online in the Annals of the New York Academy of Sciences.
